/CBIO
CBIO Stock - Crescent Biopharma, Inc.
Healthcare|BiotechnologyNASDAQ
$11.85-3.03%
$0.37 (-3.03%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+170.0%upside
Target: $32.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.73 – $11.97
TARGET (TP)$32.00
STOP LOSS$10.90
RISK/REWARD1:21.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.31
52W High$37.00
52W Low$9.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $10,000 | $75,000 | $1.16M | $10.16M |
| Gross Profit | N/A | $10,000 | $75,000 | $1.16M | $10.16M |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-68,764,000 | $-39,275,293 | $-47,403,322 | $-63,447,205 | $-51,509,390 |
| Net Income | $-71,468,000 | $-36,899,420 | $-46,688,802 | $-63,427,437 | $-51,026,903 |
| Net Margin | N/A | -368994.2% | -62251.7% | -5469.0% | -502.1% |
| EPS | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 |
Company Overview
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$27
Average Target
↑ 123.6% Upside
Now
$25
Low
$27
Average
$28
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 25th 2025 | Jefferies | Initiation | Buy | $26 |
| August 11th 2025 | H.C. Wainwright | Initiation | Buy | $25 |
| July 14th 2025 | Wedbush | Initiation | Outperform | $27 |
| June 25th 2025 | Stifel | Initiation | Buy | $28 |
Earnings History & Surprises
CBIOBeat Rate
50%
Last 20 quarters
Avg Surprise
+-0.0%
EPS vs Estimate
Beats / Misses
10/7
3 met exactly
Latest EPS
$-1.27
Q4 2025
EPS Surprise History
Q1 24
+6.7%
$-0.14vs$-0.15
Q2 24
-6.3%
$-0.17vs$-0.16
Q3 24
+5.9%
$-0.16vs$-0.17
Q4 24
-36.4%
$-0.15vs$-0.11
Q1 25
+31.3%
$-0.11vs$-0.16
Q2 25
+20.0%
$-0.04vs$-0.05
Q3 25
-83.3%
$-4.93vs$-2.69
Q4 25
-25.7%
$-1.27vs$-1.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 6, 2025 | $-1.01 | $-1.27 | -25.7% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $-2.69 | $-4.93 | -83.3% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.11 | $-0.15 | -36.4% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.14 | $-0.14 | 0.0% | = MET |
Q3 2023 | Aug 2, 2023 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.17 | $-0.17 | 0.0% | = MET |
Q1 2023 | Mar 29, 2023 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.26 | $-0.16 | +38.5% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.29 | $-0.25 | +13.8% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.31 | $-0.33 | -6.5% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q2 2021 | May 3, 2021 | $-0.32 | $-0.28 | +12.5% | ✓ BEAT |
Q1 2021 | Mar 2, 2021 | $-0.32 | $-0.32 | 0.0% | = MET |
Latest News
CBIO stock has given up its prior gain. Crescent Biopharma shares were trading higher after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical.
➖ NeutralBenzinga•Dec 4, 2025, 03:06 PM
Crescent Biopharma shares are trading higher after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical. The company secured a $185 million private placement.
📈 PositiveBenzinga•Dec 4, 2025, 02:02 PM
Market-Moving News for December 4th
➖ NeutralBenzinga•Dec 4, 2025, 12:18 PM•Also: ,
Crescent Biopharma Secures $185M Private Placement; Investors To Purchase 13.8M Ordinary Shares At $13.41 Or Pre-Funded Warrants At $13.409
📈 PositiveBenzinga•Dec 4, 2025, 11:38 AM
Sichuan Kelun-Biotech And Crescent Biopharma Partner To Develop, Commercialize Oncology Therapeutics; Cos To Advance CR-001, PD-1 x VEGF Bispecific Antibody, And SKB105 In Global Markets And China
📈 PositiveBenzinga•Dec 4, 2025, 11:35 AM
Crescent Biopharma Q3 EPS $(1.27) Beats $(1.98) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:38 PM
Crescent Biopharma To Present Preclinical Data From CR-001 Antibody For Solid Tumor Tumors At Society For Immunotherapy Of Cancer
➖ NeutralBenzinga•Nov 4, 2025, 02:11 PM
HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $25 Price Target
📈 PositiveBenzinga•Aug 27, 2025, 11:15 AM
Jefferies Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $26
📈 PositiveBenzinga•Aug 25, 2025, 11:08 AM
Frequently Asked Questions about CBIO
What is CBIO's current stock price?
Crescent Biopharma, Inc. (CBIO) is currently trading at $11.85 per share. The stock has moved -3.03% today.
What is the analyst price target for CBIO?
The average analyst price target for CBIO is $32.00, based on 1 analyst.
What sector is Crescent Biopharma, Inc. in?
Crescent Biopharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CBIO's market cap?
Crescent Biopharma, Inc. has a market capitalization of $0.16 billion, making it a small-cap company.
Does CBIO pay dividends?
No, Crescent Biopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CGEN
Compugen Ltd.
$1.52
Mkt Cap: $0.1B
HIND
Vyome Holdings, Inc.
$3.68
Mkt Cap: $0.0B
HRTX
Heron Therapeutics, Inc.
$1.30
Mkt Cap: $0.2B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
TNXP
Tonix Pharmaceuticals Holding Corp.
$17.09
Mkt Cap: $0.1B
Explore stocks similar to CBIO for comparison